HZSY(SH:600191)2023-04-27 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 130,428,802.80, representing an increase of 9,643.76 compared to the same period last year[5]. - The net profit attributable to shareholders of the listed company was CNY 44,397,530.60[5]. - The basic earnings per share for the period was CNY 0.0916[6]. - The company achieved operating revenue of RMB 130,428,802.80 in the current period, a significant increase of 9,643.76% compared to RMB 1,338,587.46 in the same period last year, primarily driven by subsidiary Yuwei Biotechnology[16]. - The net profit attributable to shareholders was RMB 44,397,530.60, reversing from a net loss of RMB -34,308,287.63 in the previous year, mainly due to long-term equity investment income and profitability from Yuwei Biotechnology[16]. - Total operating revenue for Q1 2023 reached ¥130,428,802.80, a significant increase from ¥1,338,587.46 in Q1 2022, representing a growth of approximately 9,700%[25]. - Net profit for Q1 2023 was ¥44,397,530.60, a turnaround from a net loss of ¥34,308,287.63 in Q1 2022[26]. - The total comprehensive income for Q1 2023 was ¥52,607,858.29, compared to a loss of ¥36,153,410.63 in Q1 2022[26]. - Basic and diluted earnings per share for Q1 2023 were both ¥0.0916, recovering from a loss of ¥0.0707 per share in Q1 2022[26]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,992,640,272.27, an increase of 3.27% from the end of the previous year[6]. - As of March 31, 2023, total assets amounted to RMB 1,992,640,272.27, compared to RMB 1,929,530,398.05 at the end of 2022, reflecting a growth in total assets[22]. - The total liabilities as of March 31, 2023, were RMB 458,810,719.70, up from RMB 448,308,703.77 at the end of 2022, showing a slight increase in financial obligations[22]. - The company reported a total equity attributable to shareholders of RMB 1,533,829,552.57, an increase from RMB 1,481,221,694.28 at the end of 2022, indicating strengthening shareholder value[22]. Cash Flow - The net cash flow from operating activities was CNY 21,875,626.07, reflecting a significant increase due to sales collections from a subsidiary[5][12]. - The company reported a net cash flow from operating activities of ¥21,875,626.07 in Q1 2023, compared to a negative cash flow of ¥8,888,588.42 in Q1 2022[27]. - The company's cash and cash equivalents increased to RMB 16,110,920.47 from RMB 5,545,126.70 at the end of 2022, indicating improved liquidity[20]. - The company’s cash and cash equivalents at the end of Q1 2023 amounted to ¥16,110,920.47, up from ¥66,275,736.71 at the end of Q1 2022[28]. - Investment activities resulted in a net cash outflow of ¥8,899,634.25 in Q1 2023[28]. Investments and Expenses - The investment income for the period was CNY 37,711,800, an increase of CNY 63,634,400 compared to the same period last year[10][11]. - The company achieved an investment income of ¥37,711,766.23 in Q1 2023, a significant improvement from a loss of ¥25,922,576.28 in Q1 2022[25]. - The company incurred financial expenses of ¥4,038,420.50 in Q1 2023, compared to a financial income of ¥72,260.83 in Q1 2022[25]. Operational Changes - The company experienced a 251.42% increase in contract liabilities, mainly due to advance payments received from customers[9]. - The company has seen a significant increase in sales expenses, up 114.10%, attributed to increased salaries for sales personnel at a subsidiary[9]. - The company is expanding its production capacity through the renovation of production lines, which has impacted cash flow from investing activities negatively[12]. - The company's inventory increased to RMB 191,864,606.09 from RMB 178,759,090.90, indicating a rise in stock levels[20]. - The company's long-term equity investments rose to RMB 984,011,166.24 from RMB 946,855,255.91, reflecting a strategic focus on long-term growth[21]. - The company plans to sell part or all of its shares in Huaxia Bank, holding 61,504,100 shares, which represents 0.39% of the bank's registered capital, to meet future funding needs[17].